0A5R

Calliditas Therapeutics Ab (0A5R)

Calliditas Therapeutics Ab

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:LSE:0A5R

1 2 3 4 5 6 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2023/08/18	17:21	PR Newswire (US)	FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy	LSE:0A5R	Calliditas Therapeutics Ab
2023/08/18	17:17	PR Newswire (US)	FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy	LSE:0A5R	Calliditas Therapeutics Ab
2023/08/17	14:29	PR Newswire (US)	Interim Report Q2, 2023: Calliditas Therapeutics	LSE:0A5R	Calliditas Therapeutics Ab
2023/08/15	17:52	PR Newswire (US)	Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet	LSE:0A5R	Calliditas Therapeutics Ab
2023/08/15	17:50	PR Newswire (US)	Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet	LSE:0A5R	Calliditas Therapeutics Ab
2023/07/13	15:20	PR Newswire (US)	Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib	LSE:0A5R	Calliditas Therapeutics Ab
2023/07/13	15:17	PR Newswire (US)	Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib	LSE:0A5R	Calliditas Therapeutics Ab
2023/06/21	17:12	PR Newswire (US)	Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO®	LSE:0A5R	Calliditas Therapeutics Ab
2023/06/21	17:10	PR Newswire (US)	Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO®	LSE:0A5R	Calliditas Therapeutics Ab
2023/05/30	23:18	PR Newswire (US)	Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)	LSE:0A5R	Calliditas Therapeutics Ab
2023/05/30	23:16	PR Newswire (US)	Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)	LSE:0A5R	Calliditas Therapeutics Ab
2023/05/16	14:17	PR Newswire (US)	Calliditas Therapeutics: Interim Report Q1, 2023	LSE:0A5R	Calliditas Therapeutics Ab
2023/05/16	14:14	PR Newswire (US)	Calliditas Therapeutics: Interim Report Q1, 2023	LSE:0A5R	Calliditas Therapeutics Ab
2023/05/05	22:01	PR Newswire (US)	Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023	LSE:0A5R	Calliditas Therapeutics Ab
2023/05/05	22:00	PR Newswire (US)	Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023	LSE:0A5R	Calliditas Therapeutics Ab
2023/04/28	17:54	PR Newswire (US)	Notice of annual general meeting of Calliditas Therapeutics AB (publ)	LSE:0A5R	Calliditas Therapeutics Ab
2023/04/28	17:51	PR Newswire (US)	Notice of annual general meeting of Calliditas Therapeutics AB (publ)	LSE:0A5R	Calliditas Therapeutics Ab
2023/04/27	11:40	PR Newswire (US)	Calliditas Therapeutics' 2022 Annual Report Published	LSE:0A5R	Calliditas Therapeutics Ab
2023/04/27	07:15	PR Newswire (US)	Calliditas Therapeutics' 2022 Annual Report Published	LSE:0A5R	Calliditas Therapeutics Ab
2023/04/01	00:24	PR Newswire (US)	Calliditas to participate in upcoming investor conferences	LSE:0A5R	Calliditas Therapeutics Ab
2023/04/01	00:20	PR Newswire (US)	Calliditas to participate in upcoming investor conferences	LSE:0A5R	Calliditas Therapeutics Ab
2023/03/13	12:15	PR Newswire (US)	Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA Nephropathy	LSE:0A5R	Calliditas Therapeutics Ab
2023/03/13	12:06	PR Newswire (US)	Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA Nephropathy	LSE:0A5R	Calliditas Therapeutics Ab
2023/02/23	15:41	PR Newswire (US)	Calliditas - Year-End Report, 2022	LSE:0A5R	Calliditas Therapeutics Ab
2023/02/23	15:34	PR Newswire (US)	Calliditas - Year-End Report, 2022	LSE:0A5R	Calliditas Therapeutics Ab
2023/02/02	17:46	PR Newswire (US)	Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathy	LSE:0A5R	Calliditas Therapeutics Ab
2023/02/02	17:44	PR Newswire (US)	Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathy	LSE:0A5R	Calliditas Therapeutics Ab
2023/01/31	16:22	PR Newswire (US)	Number of shares and votes in Calliditas Therapeutics	LSE:0A5R	Calliditas Therapeutics Ab
2022/12/30	17:03	PR Newswire (US)	China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy	LSE:0A5R	Calliditas Therapeutics Ab
2022/12/30	17:00	PR Newswire (US)	China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy	LSE:0A5R	Calliditas Therapeutics Ab